Status:
UNKNOWN
MR Imaging and MR Spectroscopy of HIV
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Conditions:
HIV Infections
Eligibility:
All Genders
20-65 years
Brief Summary
The Center for Disease Control and Prevention estimates that 1,148,200 Americans aged 13 years and older are living with HIV infection, including 207,600 (18.1%) who are unaware of their infection. Ac...
Detailed Description
This will be a multicenter prospective study. We will recruit ten (10) healthy participants aged 20 to 30 years to investigate the feasibility and test/retest reliability of the REPSI sequence. Twenty...
Eligibility Criteria
Inclusion
- HIV-infected between age of 20 and 65 years
- Consistently have plasma HIV RNA levels \<200 copies/mL for at least the last 12 months on a stable antiretroviral regimen with any changes made only for convenience, safety or simplicity.
- Able to provide informed consent.
Exclusion
- HIV negative
Key Trial Info
Start Date :
May 16 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05219279
Start Date
May 16 2022
End Date
March 31 2024
Last Update
May 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Los Angeles
Los Angeles, California, United States, 90095